After headline drug flops in trials, Peninsula biotech sheds 70% of its value

The South San Francisco company halted development of a drug for a rare protein-misfolding condition that causes heart problems, resulting in a $534 million drop in market value.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news